Main Article Content
Recombinant cell line development, arylsulfatase B enzyme, CRISPR/Cas9, GFP
Stable recombinant cell line development by site direct integration of a gene of interest is critical issue in therapeutic proteins production such as arylsulfatase B enzyme. Deficiency of this enzyme in human body causes mucopolysaccharidosis type VI diseases which is treated by recombinant arylsulfatase B enzyme replacement. So in this work combination of homologous recombination (HR) method through clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 and integrase system were employed to precise integration of ARSB gene into the Chinese hamster ovary (CHO) host genome for stable production of recombinant enzyme. CHO-k1 cells were cultured and transfected by green fluorescent protein (GFP) donor plasmid and pX330 vector that targeted Rosa26 locus in the host genome by CRISPR/Cas9 technique. Then GFP positive cells were selected and edited through cassette exchange integrase system to convert recombinant arylsulfatase B producer cell line. Analysis of recombinant cell lines by ELISA verified arylsulfatase B enzyme expression in all GFP negative single clones after several passages. In conclusion using a precise and specific site direct integration method for genetic manipulation can lead to stability and continuous production of recombinant protein in modified cell lines.
2. Zhu J. Mammalian Cell Protein Expression for Biopharmaceutical Production. Biotechnol. 2012;30:1158-70.
3. D Ghaderi MZ, N Hurtado, et al. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnology and Genetic Engineering Reviews 2012;28:147-76.
4. Wurm F. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393-8.
5. LM Barnes CB, AJ Dickson. Stability of protein production from recombinant mammalian cells. Biotechnol Bioeng. 2003;81:631-9.
6. M Kim POC, KA Droms, et al. .A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies. Biotechnol Bioeng. 2011;108:2434-46.
7. S Li XG, R Peng, et al. FISH‐based analysis of clonally derived CHO cell populations reveals high probability for transgene integration in a terminal region of chromosome 1 (1q13). PLoS ONE. 2016;11.
8. Y Kawabe SK, M Murakami, M, et al. Targeted knock‐in of an scFv‐Fc antibody gene into the hprt locus of Chinese hamster ovary cells using CRISPR/Cas9 and CRIS‐PITCh systems. Journal of Bioscience and Bioengineering. 2018;125:599-605.
9. F Zhu MG, AP Farruggio, et al DICE, an efficient system for iterative genomic editing in human pluripotent stem cells. Nucleic Acids Research. 2014;42(5).
10. L Cong ea. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819-23.
11. SW Cho SK, JM Kim. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013;31:230-2.
12. G Gasiunas RB, P Horvath, et al. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA. 2012;109:2579-86.
13. M Jinek ea. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-21.
14. "ARSB", Genetics Home Resource: U.S. National Library of Medicine; 2010.
15. J Hopwood GB, P Kirkpatrick Galsulfase. Nat Rev Drug Discov. 2006;5:101-2.
16. B P Zambrowicz AI, S Fiering, et al. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci 1997;94(8):3789-94.
17. D Biggs CC, B Davies Targeted Integration of Transgenes at the Mouse Gt(ROSA)26Sor Locus Methods Mol Biol. 2023;2631:299-323.
18. CM Chen JK, S Bhattacharya, et al. A comparison of exogenous promoter activity at the ROSA26 locus using a PhiiC31 integrase mediated cassette exchange approach in mouse ES cells. PLoS ONE. 2011;6(8).